Buradasınız

Anasayfa » Content

Efficacy and safety of voglibose as an add-on triple drug in patients of type two diabetes mellitus uncontrolled with glimepiride and metformin in punjabi population

Journal Name:

  • Indian Journal of Basic & Applied Medical Research

Publication Year:

  • 2014

Key Words:

Author Name
Abstract (2. Language): 
Introduction: Type 2 Diabetes mellitus is a heterogeneous group of disorders associated with both microvascular and macrovascular complications. Due to progressive nature of type 2 DM, dual / triple drug therapy produce additive effects, allows the use of submaximal doses of individual agents, less side effects and have complementary benefits on cardiovascular risk factors. Methods: The present study was designed to study the effect of voglibose on glycaemic and lipid profile as an add-on drug (agent) in patients with DM whose glycaemic status was uncontrolled with glimepiride and metformin. The present open study was conducted over a six months period. Thirty patients of type 2 DM of either sex in the age group of 30- 75 years who were on maximum doses of glimepiride 2 mg BD and metformin 500 mg BD with FBG> 126 mg/dl and HbA1c between 7- 10 % were selected at random. They were given voglibose 0.2 mg TDS as- add on triple drug. Observations and Results: The effect of triple drug combination was then observed on various parameters i.e. FBG, PPBG, HbA1c and lipid profile (Total cholesterol, TG, LDL, VLDL and HDL). At the end of 6 months it was observed that voglibose reduced FBG, PPBG and HbA1C significantly (p < 0.001). Conclusion: There was beneficial effect of voglibose on all the parameters of lipid profile (p < 0.01). The side effects like pain abdomen, headache, diarrhea, flatulence, sweating and hot flushes were also observed. Though voglibose had beneficial effect on glycaemic and lipid profile as-add on triple drug but it was associated with side effects.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-efficacy-and-safety-voglibose-add-triple-drug-patients-type-two-diabetes-mellitus-uncontrolled-glimepiride-and-metformin-punjabi-population.pdf
  • 3
110
116
  • English

REFERENCES

References: 

1. King H, Aubert RE, Herman WH . Global burden of diabetes, 1995-2025: prevalence, numerical estimates
and projections. Diabetes Care.1998; 21: 1414-1431.
2. Ramchandran A, Snehlata C, Vijay V. Burden of type 2 diabetes and its complications – The Indian
scenario. Current Sciences. 2002; 83: 1471-1476.
3. Zafar J, Bhatti F, Akhtar N, Rasheed U, Humayun S, Waheed A et al. Prevalence and risk factors for
diabetes mellitus in a selected urban population of a city in Punjab. J Pak Med Assoc 2011;61:40-7.
4. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus:
how sweet it is...or is it? Lancet. 1997; 350 (1): 4-9.
5. Hu FB, Manson JE, Stampfer MJ. Diet, Lifestyle and the risk of type 2 diabetes mellitus in women. NEJM.
2001; 345: 790-797.
6. Guillausseau PJ, Massin P, Charles MA. Glycaemic control and development of retinopathy in type 2
diabetes mellitus: a longitudinal study. Diabetes Med. 1998; 15: 151-155.
7. Grundy SM . Dietary therapy in diabetes mellitus. Diabetes Care. 1991; 14: 796- 808.
8. Powers AC. Diabetes Mellitus. In: Fauci AS, Braunwald E, Kasper DL, Stephen LH, Dan LL, Jameson LL,
Loscalzo J. Harrison’s principles of internal medicine. 17th ed. New York: Mc Graw Hill 2008; 2275- 2304.
9. Tripathi KD. Insulin, oral hypoglycaemic drugs and glucagon. In: Tripathi KD. Essentials of medical
pharmacology. 6th ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd 2008; 254-274.
10. Bailey CJ, Turner RC. Metformin. NEJM.1996; 334: 574-579.
11. Mudaliar S. New frontiers in the management of type 2 diabetes. Indian J Med Res. 2007;125: 275-96.
12. Lebovitz HE. Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001; 109
(2): 135-148.
13. Inzucchi SE.Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA.2002; 287: 360-
372.
14. Pinol. C, B. Costa. Diabetes Research and clinical practice. 1997; 38: 33-40.
115
Indian Journal of Basic and Applied Medical Research; June 2014: Vol.-3, Issue- 3, P. 111-116
110
www.ijbamr.com P ISSN: 2250-284X , E ISSN : 2250-2858
15. Kazuya S, Masaaki S, Junya H, Yasushi H, Yutaka H. Improvement of insulin sensitivity and dyslipidemia
with a new glucosidase inhibitor, Voglibose in nondiabetichyperinsulinemic subjects. Metabolism.1996; 45
(6): 731-737.
16. Derosa G, Salvedeo S, Angelo A, Ferrari I, Moreu R, Palumbo I et al. Metabolic effect of repaglinide or
acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double
blind, cross over, clinical trial. Informa Healthcare. 2009; 25 (3): 607-615.
17. Mughal MA, Memon MY, Zardari MK, Tanwani RK, Ali M. Effect of acarbose on glycaemic control,
serum lipids and lipoproteins in type 2 diabetes. J Pak Med Assoc. 2000; 50 (5): 152-156.
18. Iwamoto Y, Kashiwagi A, Yamada N, Terao S, Mimori N, Suzuki M et al. Efficacy and safety of
vildagliptin and voglibose in Japanese patients with type 2 diabetes; a 12 week, randomized, double blind,
active controlled study. Diabetes obes metab.2010; 12 (8): 700-708.
19. .United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of
macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703-713.

Thank you for copying data from http://www.arastirmax.com